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Background: Somatic mutations of the epidermal growth factor receptor (EGFR) are reportedly associated with
various responses in non-small cell lung cancer (NSCLC) patients receiving the anti-EGFR agents. Detection of the
mutation therefore plays an important role in therapeutic decision making. The aim of this study was to detect
EGFR mutations in formalin fixed paraffin embedded (FFPE) samples using both Scorpion ARMS and high resolution
melt (HRM) assay, and to compare the sensitivity of these methods.
Results: All of the mutations were found in adenocarcinoma, except one that was in squamous cell carcinoma. The
mutation rate was 45.7% (221/484). Complex mutations were also observed, wherein 8 tumours carried 2 mutations
and 1 tumour carried 3 mutations.
Conclusions: Both methods detected EGFR mutations in FFPE samples. HRM assays gave more EGFR positive results
compared to Scorpion ARMS.
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Lung cancer is the main cause of cancer-related death
worldwide, with over one million deaths per year [1].
Lung carcinoma is divided into two groups – non-small
cell lung cancer (NSCLC) and small cell lung cancer
(SCLC), based on its clinical and histopathological
features. The NSCLC accounts for about 80% of lung
cancer and can be further divided into three subclasses:
adenocarcinoma; squamous cell carcinoma; and large
cell carcinoma. In Malaysia, of all the cancer cases, lung
cancer ranked second in males and sixth in females [2].
Despite advances in molecular pathology and improve-
ment in screening programs, patients’ prognosis remains
poor. Most lung cancer patients are diagnosed in the
advanced or metastatic stages with a median survival of* Correspondence: ykcheah@medic.upm.edu.my
1Department of Biomedical Sciences, Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia
Full list of author information is available at the end of the article
© 2013 Shi Yeen et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orabout 4–5 months while the 1-year survival rate is less
than 10%, if left untreated [3].
Epidermal growth factor receptor (EGFR) is a trans-
membrane glycoprotein encoded by a gene located at
the short arm of chromosome 7. Activation of the recep-
tor through the binding of a ligand stimulates a range of
cellular functions such as cell proliferation, differenti-
ation, adhesion, migration and survival. Mutation in the
EGFR would result in continuous tyrosine kinase activity
regardless of the presence of stimulus which in turn,
leads to the development of lung tumours [4]. In 2004,
EGFR mutations in NSCLC were discovered to be asso-
ciated with patients’ responsiveness to epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKI)
[5-7]. Since then, EGFR mutation has become an
important biomarker in lung cancer screening as identi-
fying this biomarker can predict which patient will bene-
fit from EGFR targeted therapy [8].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more common in tumours from female patients, Asian
origin, never-smoker and adenocarcinoma histology
[6,9]. These mutations were reported to be found in
exon 18 to 21 located in the intracellular TK-containing
domain. Approximately 90% of the mutations were
detected in the following two hotspots: in-frame dele-
tions in exon 19 and a missense mutation at codon 858
(L858R) in exon 21 [7,10,11]. These mutations are often
termed classical activating mutations [12]. Besides clas-
sical mutations, other non-classical mutations in exon
18 to 21 have also been reported. They include point
mutations in exon 18 (G719X) and exon 21 (L861Q), as
well as substitution mutation (S768I) and insertions in
exon 20. It is uncommon to detect non-classical muta-
tions and patients harbouring these mutations have vari-
able responses to EGFR TKIs. Moreover, there were
cases of complex mutations pattern whereby two or
more concomitant sites of EGFR mutations co-exist
within a single patient [13-15].
Because of the high rates of EGFR mutation in Asian
populations, routine EGFR mutation testing is essential
to identify which patient will benefit from the EGFR
targeted therapy. Direct sequencing has been the most
widely used method in EGFR mutation testing as this
method has the capability of detecting all mutations,
both known and unknown. However, its time consuming
and limited sensitivity due to contamination of non-
malignant cells in samples render researchers to look for
alternative testing methods that are faster and more
sensitive [16,17].
The Scorpion Amplification Refractory Mutation Sys-
tem (ARMS) combines two technologies, namely ARMS
and Scorpion, to detect EGFR mutations in real-time
PCR reactions. ARMS allows allele specific amplification
while Scorpion molecules which consist of PCR primer,
covalently linked to a probe held in a hairpin loop
conformation by the presence of complementary stem
sequence at the 5′ and 3′ ends. When both technologies
are used in combination, a highly sensitive and fast
method in single-base mutation detection was achieved
[18,19].
Using the Scorpion ARMS kit and HRM assay, we aim
to detect major EGFR mutations and to determine the




Tumour samples, in the form of unstained sections from
formalin fixed, paraffin-embedded (FFPE) tissue block,
from patients with NSCLC were received in Sime Darby
Medical Centre, Subang Jaya, Malaysia. The samples
were assessed by pathologists from Sime Darby MedicalCentre prior to the testing. A total of 484 patients were
recruited for this study. Of the 484 samples, 467 were
adenocarcinoma, 12 were squamous cell carcinoma, 3 were
large cell carcinoma, and 2 were of other histology. This
study was approved by Sime Darby independent ethics
committee (IRB reference number: 201102.3), by Universiti
Putra Malaysia ethics committee (Reference number:
UPM/FPSK/PADS/T7-MJKEtikaPer/F01 (JSB_Aug(11)03))
and National Institute of Health, Malaysia (Date: 12-
07-2011).
DNA extraction
Genomic DNA was isolated from FFPE tissue section using
QIAamp DNA FFPE Tissue Kit (QIAGEN) according to
the manufacturer’s instructions. Extracted DNA was
spectrophotometrically quantified using NanoPhotometer
(Implen) and was stored at −20°C until use.
EGFR mutation detection
EGFR PCR Kit (QIAGEN Manchester Ltd., United
Kingdom), which combined two technologies, the
Amplification Refractory Mutation System (ARMS) and
Scorpion, was used to detect mutations in real-time
PCR reactions. All reactions were done in 25 μl volumes
using 5 μl of template DNA, 16 μl of reaction mix, 0.2 –
0.8 μl of Taq polymerase and PCR grade water.
HRM assays
PCR for HRM analysis was performed in 0.2 ml tubes
on the Rotor-Gene 6000 using KAPA HRM FAST PCR
kit. The reaction mixture in a 20 μl final volume
contained; 1× KAPA HRM FAST master mix, 2.5 mM
MgCl2, 200–400 nM forward primer, 200–400 nM
reverse primer, 5 ng of genomic DNA and PCR grade
water. The cycling and melting conditions for EGFR
exons 18 to 21 were as follow; one cycle of 95°C for
15 min; 50–70 cycles of 95°C for 10 s, 65°C for 10 s with
an initial 10 cycles of touchdown (1°C/cycle), 72°C for
30 s; one cycle of 97°C for 1 min and a melt from 70°C
to 95°C rising 0.2°C per second [20]. All samples were
tested in duplicates.
Primer sequences that yield shorter amplicons were
used in HRM assays. The sequences, retrieved from Do
et al. (2008), are shown in Table 1. Primer for exon 20
was divided into two fragments (20a and 20b) to avoid
the exonic SNP, c.2361G>A, because melting pattern
arising from the SNP could not be readily extinguished
from mutation by HRM.
HRM analysis
Data were analysed using the accompanying software
(Rotor Gene). All samples were plotted according to
their melting profiles. Under the difference graph, melt-
ing profiles of the samples were compared to that of the
Table 1 HRM primer sequences
Exon Primer name Sequence Amplicon
size
18 EGFR_ex18_F 5′-CATGGTGAGGGCTGAGGTGA-3′ 199 bp
EGFR_ex18_R 5′-CCAGAGG(A*)CTGTGCCAGGG
AC-3′
19 EGFR_ex19_F 5′-GTGCATCGCTGGTAACATCCA-3 250 bp
EGFR_ex19_R 5′-AAAGGTGGGCCTGAGGTTCA-3
20a EGFR_ex20a_F 5′-AAGCCACACTGACGTGCCTCT-3′ 121 bp
EGFR_ex20a_R 5′-GCGTGATGAG(G*)TGCACGGT-3′
20b EGFR_ex20b_F 5′-CCTCCACCGTGCA(C*)CTCATC-3′ 146 bp
EGFR_ex20b_R 5′-CCCGTATCTCCCTTCCCTGA-3′
21 EGFR_ex21_F 5′-CCTCACAGCAGGGTCTTCTCTG-3′ 210 bp
EGFR_ex21_R 5′-TGGCTGACCTAAAGCCACCTC-3′
Table 2 Association of each variable with EGFR mutation
Characteristics No. EGFR mutation No. (%) P
Patients 484 221 (45.7)
Gender
Male 253 81 (32.0) <0.001
Female 231 140 (60.6)
Missing data 0
Age, yr
≤ 60 244 119 (48.8) 0.163





Chinese 293 136 (46.4) 0.747
Malay 143 62 (43.4)
Indian 26 15 (57.7)
Others 7 2 (28.6)
Missing data 15 6 (40.0)
Stage
I/ II 5 1 (20.0) 0.385
III/ IV 72 33 (45.8)
Not specified 348 160 (46.0)
Missing data 59
Histological type
Adenocarcinoma 467 220(47.1) 0.004
Squamous cell carcinoma 12 1 (8.3)
Large cell carcinoma 3 0 (0)
Others 2 0 (0)
Missing data 0
Degree of differentiation
Well differentiated 2 2 (100) 0.074
Moderately differentiated 42 20 (47.6)
Poorly differentiated 33 10 (30.3)
Undifferentiated 1 0 (0)
Not specified 41 21 (51.2)
Missing data 365
Smoking history
Current 10 5 (50.0) 0.191
Former 3 1 (33.3)
Never 25 17 (68.0)
Missing data 446 198 (44.4)
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nificant deviations from the horizontal line indicate the
presence of mutation and were recorded as HRM posi-
tive. HRM results were compared with results from
Scorpion ARMS method to evaluate the sensitivity of
the methods in EGFR mutation detection.
Statistical analysis
Chi-square test or Fisher exact tests (SPSS version 16.0;
SPSS Inc., Chicago, Ill) were used to compare EGFR mu-
tation status with clinicopathologic characteristics and
patient’s demographic including gender, smoking status,
and ethnicity. An interrater reliability analysis using the
Kappa statistic was performed to determine consistency
between the two methods, Scorpion ARMS and HRM.
Results
Patient characteristics
From January 2011 through April 2012, a total of 484 pa-
tients with non-small cell lung cancer were tested for
EGFR mutations. Patient’s clinical characteristics and their
association with EGFR mutation are shown in Table 2.
Among these, 467 patients had adenocarcinoma, 12 pa-
tients had squamous cell carcinoma, 3 patients had large
cell carcinoma, and 2 patients had adenosquamous carci-
noma. Among the patients with adenocarcinoma, 220
cases were found to harbour at least 1 mutation in the
EGFR gene. And in the remaining 17 non-
adenocarcinoma cases, only one had an EGFR mutation,
and it occurred in a female patient with squamous cell
carcinoma.
Mutations in the EGFR gene were found in 221 of 484
patients (45.7%) and were more frequent in women
(60.6%, p<0.001) and in patients with adenocarcinoma
histology (47.1%, p=0.004). Although not statistically sig-
nificant, the frequency of EGFR mutations was higher in
Chinese (46.4%), in patients aged less than or equal to
Table 3 Summary of EGFR mutations detected by
Scorpion ARMS
Exon Mutations Frequency Percentage (%)
18 G719X 4 1.7
19 Deletions 134 58.0
20 S768I 13 5.6
21 L858R/ L861Q 80 34.6
Total 231 100
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in moderately differentiated tumour cells (47.6%), and in
never smokers (68%). Median age of patients was 60
(range, 21–92).
EGFR mutations detection by Scorpion ARMS
EGFR mutations were detected in 221 patients (45.7%)
(Figure 1). The most common mutation was deletions in
exon 19, comprising 58.9% (134/231) of all mutations
found, followed by 33.8% (78/231) exon 21 mutation.
Thirteen mutations in exon 20 (5.6%) and four muta-
tions in exon 18 (1.7%) were also detected (Table 3).
Interestingly, all mutations in exon 18 were found in the
presence of another mutation.
Complex mutation patterns were also detected in the
patients. Eight double mutations and one triple mutation
were detected in nine patients giving rise to 231 muta-
tions in 221 patients. Among them, five patients had the
classical mutation pattern of deletions or L858R. Two
concurrent deletions and L858R mutations were also
observed (Table 4).
EGFR mutation detection by HRM analysis
In order to demonstrate the capability of HRM assay in
EGFR mutation detection, a total of 236 NSCLC samples
were tested by HRM for the detection of EGFR mutations
in exon 18 to 21 (Figure 2). The HRM assays yielded 19,Figure 1 Amplification plots from Scorpion ARMS assay. Panel A: Amp
showing the presence of deletions in sample 408. Panel C: Amplification p120, 18 and 78 results that were scored as HRM positive
in exon 18 to 21 respectively. All mutations identified by
SARMS were correctly identified by HRM assays except
for 2 samples – one each in exon 19 and 21.
However, HRM indicated more positive samples than
Scorpion ARMS for all the EGFR exons. A total of 33
samples were positive only by HRM (Table 5). There were
15, 21, 8 and 4 HRM positive only results from exons 18
to 21 respectively (Table 6). Among these, 1 sample was
positive in three HRM assays, 13 samples were positive in
two assays, and 19 samples were positive in a single assay.
Discussion
Currently, direct sequencing is considered the “gold
standard” in nucleic acids studies, but its limited sensi-
tivity, high cost and long turnaround time limits its
practicality in diagnostic setting. To produce goodlification plots of EGFR positive controls. Panel B: Amplification plot
lot showing the presence of L858R mutation in sample 429.




Exon 19 deletions 128 50 78
Exon 20 insertions 5 2 3
Exon 20 S768I 2 1 1
Exon 21 L858R 74 23 51
Exon 21 L861Q 3 1 2
Exon 18 G719X + Exon 19 deletions 1 0 1
Exon 18 G719X + Exon 20 S768I 2 1 1
Exon 18 G719X + Exon 21 L861Q 1 1 0
Exon 19 deletions + Exon 20 insertions 3 1 2
Exon 19 deletions + Exon 21 L858R 1 0 1
Exon 19 deletions + Exon 20 insertions +
Exon 21 L858R
1 1 0
Total 221 81 140
Table 5 Comparison of results from scorpion ARMS and
HRM assays
Scorpion ARMS
HRM Positive Negative Total
Positive 186 33 219
Negative 2 15 17
Total 188 48 236
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amount and in relatively good condition are required.
However, these requirements are often hard to fulfil as
lung tumour samples are small and contain only a small
proportion of neoplastic cells, therefore resulting in aFigure 2 Difference plots of EGFR exons 18–21. Panel A: The difference
(S162 in yellow, S455 in pink, S49/12 in green and S87/12 in blue). Panel B
positive samples (S101 in yellow, S047 in pink, S063 in brown, S552 in gree
difference plot of EGFR exon 20 shows melting profile for four positive sam
The difference plot of EGFR exon 21 shows melting profile for seven positi
S211/12 in green, S212/12 in dark blue, S217/12 in orange and S220/12 inreduced sensitivity of sequencing. Besides, special instru-
mentation are required to perform direct sequencing,
which in turn prompted the development of alternative
methods that are more sensitive, faster, easier to
perform, and at a reduced cost [11,20].
High resolution melting (HRM) is an emerging tech-
nique for rapid detection of DNA sequence variation
that provides enormous potential to meet clinical
demands [21]. HRM involves precise monitoring of the
changes in fluorescence caused by the release of an
intercalating DNA dye from a double stranded DNA
which is denatured by increasing temperature. This
technique characterizes the melting or dissociation be-
haviour of double-stranded PCR products based on the
transition of double stranded DNA to single strandedplot of EGFR exon 18 shows melting profile for four positive samples
: The difference plot of EGFR exon 19 shows melting profiles for seven
n, S065 in blue, S046 in purple and S048 in orange). Panel C: The
ples (S13 in yellow, S19 in purple, S28 in green, S68 in pink). Panel D:
ve samples (S105/12 in purple, S115/12 in light blue, S210/12 in brown,
pink).
Table 6 Summary of EGFR mutation testing by Scorpion
ARMS and HRM
Exon Scorpion ARMS positive HRM positive HRM positive only
18 4 19 15
19 100 120 21
20 10 18 8
21 75 78 4
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technique is that it does not involve any post-PCR process-
ing as PCR amplification and melting curve analysis are
performed within the same tube, thus reducing the chances
of samples contamination and cross-contamination [22].
Compared to the closed tube system of HRM, normal
DNA sequencing procedure involves post-PCR processing
such as gel electrophoresis and gel purification before the
sequencing process, thus increasing the chances of external
contamination.
In this study, we compared two methods in the detec-
tion of EGFR mutations in NSCLC patients. Our find-
ings showed that EGFR mutations were detectable in
genomic samples extracted from FFPE tissue obtained
from patients with NSCLC and that both Scorpion
ARMS and HRM are useful methods for detection of
EGFR mutations. The frequency of EGFR mutation sta-
tus detected by Scorpion ARMS was statistically signifi-
cantly more frequent in women (140/233 or 63.3%) than
in men (81/253 or 36.7%), and more frequent in adeno-
carcinomas (220/467 or 47.1%) than in other histology
(1/17 or 5.9%). Previous studies revealed that EGFR mu-
tations were uncommon in non-adenocarcinomas [14].
In this study, we detected an exon 19 deletion in one
female patient with squamous cell carcinoma. The muta-
tion rate (45.7%) observed in our study is in concord-
ance with previous findings [6,23-25]. The high overall
mutation rate further verifies that the EGFR mutations
were more common in Asian population. Evidently,
deletions in exon 19 and point mutations in exon 21 are
the two most common drug-sensitive EGFR mutations
seen in NSCLC. These two mutations made up of 92.7%
of total EGFR mutations detected in this study which is
in agreement with previous studies [18,19,26].
Also, we identified 9 patients (4.1%) with complex
mutation patterns. Among the patients with these muta-
tions, 4 cases were found in Chinese patients, 3 in Malay
patients, 1 in Indian and 1 other ethnicity. Complex
EGFR mutations were reported to be more common in
Asian lung cancer patients. However, information about
the effects of complex EGFR mutations on patients’
response to EGFR TKI was very limited. Furthermore,
findings from previous studies varied between each
other. Tam et al. (2009) reported that EGFR double mu-
tants showed attenuated responses to gefitinib comparedto single classical mutations [27]. On the contrary, a
study by Wu et al. (2008) showed that patients with
complex EGFR mutations with the classical mutation
pattern response better to gefitinib than those without
the classical mutation pattern. Also, these patients
showed longer progression free survival and overall
survival times after receiving the therapy [13].
Based on the results from Scorpion ARMS, we
selected a total of 236 samples, consisting both EGFR
positive and negative mutation status, and performed
HRM assays on these samples to assess its capability in
detecting EGFR mutation as precision in identifying mu-
tations is the fundamental in all mutation scanning
methods. This study shows the reliability of HRM ana-
lysis in EGFR mutation detection in a panel of selected
samples. All mutations identified by Scorpion ARMS
were correctly identified in HRM analysis except for 2
samples – one from exon 19 assay and another from
exon 21 assay. One possible explanation for this is the
low level of mutation in the samples which were beyond
the limit of HRM detection. The Scorpion ARMS and
results from HRM assays agreed that 186 of 236 were
positive and 15 were negative. The interrater reliability
for the methods was found to be statistically significant
with a value of Kappa = 0.40 (p <.0.001) which indicates
fair agreement between the two methods [28].
One of the drawbacks of extracting DNA from FFPE
material is the low yield. Thus, additional PCR cycles
were needed to achieve sufficient amplification. In a
study by Do et al. (2008), it was found that insufficient
amplification causes a right shift of the melting curves
relative to the wild-type curves in normalized plots. And
by increasing the amplification cycle number to 60, the
melting curves were corrected and can be reliably com-
pared to the wild-type during analysis [20]. Depending
on the degree of DNA degradation, the amount of
amplifiable templates varies in each sample although all
were adjusted to the same concentration (5 ng/μl).
Conclusions
In conclusion, both Scorpion ARMS and HRM were
successfully performed on genomic samples extracted
from FFPE tumours. Overall, HRM compares well with
the Scorpion ARMS kit. HRM indicated more positive
samples than Scorpion ARMS for all the EGFR exons.
Nevertheless, it remains to be determined whether these
results were true mutation or merely false positive.
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